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Abstract: We employed Illumina 450 K Infinium microarrays to profile DNA methylation (DNAm)
in neuronal nuclei separated by fluorescence-activated sorting from the postmortem orbitofrontal
cortex (OFC) of heroin users who died from heroin overdose (N = 37), suicide completers (N = 22)
with no evidence of heroin use and from control subjects who did not abuse illicit drugs and
died of non-suicide causes (N = 28). We identified 1298 differentially methylated CpG sites
(DMSs) between heroin users and controls, and 454 DMSs between suicide completers and controls
(p < 0.001). DMSs and corresponding genes (DMGs) in heroin users showed significant differences
in the preferential context of hyper and hypo DM. HyperDMSs were enriched in gene bodies and
exons but depleted in promoters, whereas hypoDMSs were enriched in promoters and enhancers.
In addition, hyperDMGs showed preference for genes expressed specifically by glutamatergic as
opposed to GABAergic neurons and enrichment for axonogenesis- and synaptic-related gene ontology
categories, whereas hypoDMGs were enriched for transcription factor activity- and gene expression
regulation-related terms. Finally, we found that the DNAm-based “epigenetic age” of neurons from
heroin users was younger than that in controls. Suicide-related results were more difficult to interpret.
Collectively, these findings suggest that the observed DNAm differences could represent functionally
significant marks of heroin-associated plasticity in the OFC.
Keywords: DNA methylation; drug addiction; heroin; suicide; brain; neurons; human
Genes 2017, 8, 152; doi:10.3390/genes8060152 www.mdpi.com/journal/genes
Genes 2017, 8, 152 2 of 18
1. Introduction
Opioid overdose is now the second leading cause of accidental death among adults in the U.S. [1,2].
Prescription opioids are believed to have served as a gateway to the use of heroin which is more
readily available and less expensive than prescription medications [3–5]. The opioid epidemic has
raised attention to the relatively limited knowledge about the pathophysiology underlying heroin use
disorder, particularly from insights gained through interrogation of the human brain.
As with other drugs of abuse, the susceptibility to opioid addiction is known to be influenced
roughly equally by genetic and environmental factors [6–8], suggesting an important role for epigenetic
regulation. Epigenetic mechanisms mediate long-term changes in gene expression without changes
in DNA sequence [9,10]. Recent studies in animal models provide robust evidence that repeated
exposure to drugs of abuse induces changes in gene expression through alterations in all major
modes of epigenetic regulation (e.g., cytosine DNA methylation (DNAm), histone modifications,
and non-coding RNAs), and in several instances, the contribution of such epigenetic changes to
addiction-related behavioral abnormalities in animals has been directly demonstrated [11]. Specific
examples include changes in the level of the transcription-activating histone modification H3K27ac
in different brain regions in several experimental models of drug addiction [12,13], alterations of the
repressive histone marks H3K9me2/3 in the nucleus accumbens during chronic cocaine or opioid
addiction [14,15], and a plethora of epigenetic mechanisms which have recently been implicated in the
downregulation of BDNF expression in the ventral tegmental area after chronic opioid exposure [16].
DNAm is a stable mostly repressive epigenetic modification that is extremely important for both
the establishment of cell-type-specific phenotypes in the nervous system [17] and the mediation of
environmentally induced changes in the adult brain including memory formation, stress responses,
and depression [18–20]. Changes in levels of DNAm at specific gene loci, as well as changes in levels
of modifying proteins, have also been observed after exposure to drugs of abuse, with a recent study
supporting the role of DNA hydroxymethylation (5 hmC) in chronic cocaine addiction [21,22]. Whereas
such information from animal studies is valuable, increasing the limited knowledge about the DNAm
landscape in the brains of humans with substance use disorders is critical for the development of novel
more effective treatments.
Several features of DNAm were considered in the design of the present study. First, recent studies
indicate that the composition and dynamics of DNAm are not only distinct in the brain compared to
other tissues [23,24], but also differ significantly across different regions of the brain [25,26]. Studies
of cognitive processes that accompany drug addiction during the last decade suggest that addiction
involves neuroplasticity mechanisms similar to traditional models of learning and memory [27]
and that these mechanisms underlie the role of the medial (m) prefrontal cortex (PFC) in drug
self-administration and the long-lasting propensity to relapse [28–30]. Moreover, human imaging
studies [31–33] and rodent studies that employed a reinstatement model of drug relapse [34–36]
strongly suggest involvement of the ventral aspects of the mPFC in addiction. In particular, these
studies suggest that diminished output from the ventral mPFC contributes to drug seeking behavior
by impairing the ability to actively inhibit behavioral responses to drug-conditioned stimuli. For these
reasons, in the present study we examined DNAm in autopsy specimens from the medial orbital frontal
cortex (mOFC)—a ventral subregion of the mPFC—which participates in regulating goal-directed
behavior and decision-making and has been implicated in drug addiction by human imaging and
animal studies [37,38].
In addition, a number of studies have reported DNAm alterations in the human brain that
are associated with addiction (specifically with alcohol use disorder, e.g., [39,40]). These studies
were performed using bulk (cellularly heterogeneous) tissues. However, several recent reports
have clearly demonstrated robust differences in DNAm and histone modification patterns between
neuronal and glial cell populations in human and rodent brains [24,41,42]. These cell type-specific
epigenetic landscapes might ultimately determine the selective vulnerability to neurodevelopmental or
environmental insults that could culminate in drug addiction. Thus, in order to increase the likelihood
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of identifying cell type-specific signatures of heroin addiction-associated epigenetic variations, our
studies employed neuronal cells that were separated from glia using fluorescence activated nuclei
sorting (FANS).
Recently, a highly accurate multi-tissue epigenetic biomarker of tissue age (“epigenetic clock”,
also known as “Horvath clock”) based on DNAm levels has been introduced [43]. This approach
allows one to estimate the “epigenetic age” of any organ, tissue, or cell type including sorted
neurons. Mathematically it is defined as a weighted average across 353 CpG sites. The resulting
age estimate (in units of years) is referred to as “DNA methylation age” (DNAm age) or “epigenetic
age”. Recent studies support the idea that epigenetic age estimates can serve as biomarkers of
biological age. For instance, the epigenetic age of blood has been found to be predictive of all-cause
mortality [44–48], frailty [49], lung cancer [50], and cognitive and physical functioning [51]. Further,
the utility of the epigenetic clock method using various tissues and organs has been demonstrated
in applications surrounding Alzheimer’s disease [52], centenarian status [47,53], development [54],
Down syndrome [55], HIV infection [56], Huntington’s disease [57], obesity [58], lifetime stress [59],
and Parkinson’s disease [60]. It was also shown that different brain regions have different DNAm age,
with the cerebellum displaying the youngest age of all tested regions [53].
In the present report, we compared DNAm in neuronal populations of the mOFC among
individuals who abused heroin and died of heroin overdose, suicide completers without any evidence
of heroin use, and a control group consisting of specimens from psychiatrically normal individuals
who died of non-suicide causes and did not abuse illicit drugs. All brain specimens came from the
same brain collection. Suicide completers were included as a comparison group with a different
pathophysiology. The study revealed significant methylation disturbances in heroin abusers that
may represent a functionally relevant epigenetic signature of heroin addiction in the human brain.
Moreover, while the epigenetic age of neurons from the suicide and control individuals did not differ
from their biological age, the epigenetic age of neurons from heroin users was younger.
2. Materials and Methods
2.1. Subjects and Tissue
Human postmortem brain specimens were obtained from our Brain Collection at the Icahn
School of Medicine at Mount Sinai that has been extensively used for many molecular and epigenetic
studies [42,61–69]. Brains were collected at autopsy at the Department of Forensic Medicine,
Semmelweis University (Hungary) or National Institute of Forensic Medicine, Karolinska Institutet
(Sweden). All material was obtained under approved local ethical guidelines. The cohort (N = 88)
consists of a Hungarian/Swedish population of heroin abusers who died of heroin overdose (N = 37),
suicide completers without any evidence of heroin use (N = 22), and control subjects who did not
abuse illicit drugs and died of non-suicide causes (such as cardiac failure, viral infection, or an accident;
N = 29) (Supplementary Materials Table S1). One of the control subjects was later excluded from the
analyses due to ambiguity of sex, which was discovered during the data processing. The cause and
manner of death and possible psychiatric diagnoses were determined by a forensic pathologist after
evaluating autopsy results, circumstances of death, data from extensive toxicological testing, police
reports, family interviews, and medical records. Exclusion criteria were postmortem interval (PMI)
of >24 h, HIV-positive status, history of alcoholism, use of illicit drugs (other than heroin in heroin
abusers) and the presence of Axis 1 psychiatric disorders. All specimens from heroin users included
in the study were from individuals who died from heroin intoxication. These individuals were not
receiving methadone or buprenorphine treatment, and had positive blood and/or urine levels for
opiates at the time of death. Their average time of heroin use where this information was available
(N = 23 individuals) was 3.75 years (ranging from 0.5 to 10 years). The control and suicide groups
were negative for blood opiates and had no history of any drug addiction. All suicide subjects died
from hanging. The control subjects died from myocardial infarction, pulmonary embolism, electric
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shock or viral infection. Subjects from all 3 groups showed negative toxicology for other common
drugs of abuse and common therapeutic agents. EtOH was detected in the blood and/or urine of
6 heroin, 5 suicide, and 3 control subjects and EtOH levels were not significantly different among
groups. Nicotine toxicology was not conducted, but tobacco use is frequent in the general population
from which all the subjects were collected.
Autopsy brain specimens were cut coronally in 1 cm slabs, frozen, and kept at −80 ◦C. From these
specimens we harvested the ventral extent of the PFC commonly referred to as the orbital frontal cortex
(OFC; Brodmann area 11). Specifically, we dissected the regions containing the medial orbital (MOrG)
and inferior orbital (IOrG) gyri just anterior to the transversely running orbital sulcus. The region was
dissected in a single block bounded by the olfactory sulcus medially and the inferior orbital sulcus
laterally as described previously [42].
2.2. Nuclei Separation by Fluorescence Activated Nuclei Sorting (FANS)
Cell structure is not preserved in frozen autopsy brain specimens. However, the nuclei of different
cell types remain intact. Antibodies against the RNA-binding protein NeuN, which is expressed
exclusively in the neuronal nuclei, have been used to separate neuronal from glial nuclei using
FANS (e.g., [24,41,70–73]). In a recent study, we optimized previously published FANS protocols
by employing the DNA-binding dye 7-AAD and anti-NeuN antibodies directly conjugated with the
fluorophore [42]. This protocol was used in the present study. In short, for each specimen, mOFC
tissue was ground using mortar and pestle on liquid nitrogen, resuspended in ice-cold Lysis Buffer
(0.1% Triton, 0.32 M sucrose, 5 mM CaCl2, 3 mM MgCl2, 10 mM Tris-HCl), filtered through a cell
strainer, and centrifuged for 5 min at 300 g. The pellet was resuspended in Blocking Buffer (1% goat
serum, 2 mM MgCl2, TBS) and incubated for 45 min with Alexa488-conjugated anti-NeuN antibodies
(EMD Millipore, Billerica, MA, USA) (1:1000 dilution). Next, a second centrifugation step (15 min,
2800 g) through a layer of 1.1 M sucrose was done, and the resulting pellet was resuspended in PBS.
The DNA dye 7-AAD (Sigma-Aldrich, St. Louis, MO, USA) was added to a final concentration of
2 µg/mL, and the sample was subjected to the FANS procedure using Vantage with DiVa (excitation
wavelength 488 nm). Finally, the sorted nuclear fractions were precipitated by centrifugation at
4000 rpm for 20 min at 4 ◦C and stored frozen at−80 ◦C until DNA isolation. The latter was performed
using proteinase K treatment and two rounds of phenol extraction followed by ethanol precipitation.
This protocol allowed us to routinely obtain well-separated NeuN(+) and NeuN(−) nuclear
fractions, with the width of separation reaching up to an order of magnitude of the NeuN signal
intensity [42]. In addition, the DNA content of both fractions was well-defined because aggregates,
nuclei of dividing cells, and debris were excluded in the process of sorting. Validation of the
cell-type specificity of the obtained neuronal and non-neuronal populations was done previously by
demonstrating the enrichment for the known neuronal or glial-specific transcripts in RNA samples
extracted from the sorted NeuN(+) and NeuN(−) populations, respectively [42]. We estimated
the proportions of neurons and glia in our FANS-separated neuronal nuclear preparations using
the algorithm from [74] and NeuN(+) and NeuN(−) reference data from [41] (see [75] for details).
For comparison, we also included DNA methylation data for 6 NeuN(−) (glial) specimens from
our published study [42]. The results are presented in a Supplementary Materials Figure S1, and
demonstrate high purity of our neuronal nuclear preparations.
2.3. DNA Methylation Measurement and Analysis
For each specimen, DNA was extracted from the neuronal fraction and subjected to sodium
bisulfite treatment to generate methylation-specific base changes before hybridization. Batch effect
was minimized by performing the bisulfite treatment simultaneously for all 88 specimens, and by
randomizing the placement of heroin, suicide and control samples across the arrays.
DNA samples were bisulfite converted using EZ DNA methylation kit (Zymo Research, Tustin,
CA, USA). Specifically, 500 ng of high quality genomic DNA (A260/260 ≥ 1.8; A260/230 = 2.0–2.2)
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was denatured by incubation with NaOH-containing Zymo M-Dilution buffer for 15 min at 37 ◦C.
Next, the denatured DNA was incubated with bisulfite-containing CT-conversion reagent for 16 h
at 50 ◦C in a thermocycler. Every 60 min the reaction was heated to 95 ◦C for 30 s. All 88 samples
were processed on the same plate. The Infinium methylation assay was carried out as described [76].
In short, 4 µL of bisulfite-converted DNA (~150 ng) was used in the whole-genome amplification
reaction. After amplification, the DNA was fragmented enzymatically, precipitated and re-suspended
in hybridization buffer. All subsequent steps were performed following the standard Infinium protocol
(User Guide part #15019519 A). The fragmented DNA was dispensed onto the HM450K Bead-Chip [77],
which was followed by hybridization in a hybridization oven for 20 h. After hybridization, the array
was processed through a primer extension and an immunohistochemistry staining protocol to allow
detection of a single-base extension reaction. Finally, the Bead-Chip was coated and then imaged on an
Illumina iScan (Illumina, San Diego, CA, USA). The same iScan array scanner was used for processing
all samples.
All 88 samples that were used in this study passed Illumina quality control requirements and
received a status of “Successful Sample”. The data were further evaluated for quality using the “minfi”
R/Bioconductor package [78]. All samples passed by the suggested criteria of median M and U
intensities greater than 10.5. All but one sample passed a test for concordance between estimated and
reported sex. This sample was removed from the subsequent analyses (see Supplementary Materials
Table S1). The data were then pre-processed with stratified quantile normalization described in
the minfi paper [78]. Probes with annotated/dbSNP-labeled SNPs in the single base extension or
target CpG site were filtered, as were probes on the sex chromosomes, leaving 456,513 probes for
subsequent analysis.
For differential methylation analysis, we employed limma R/Bioconductor package to perform
linear regression and moderated t-statistics (with empirical Bayes) adjusting for age, sex and tissue pH
and the first four “negative control” principal components, which typically capture batch and slide
effects as described previously [75]. Differentially methylated (DM) CpG sites (DMSs) were assigned to
genes using the distanceToNearest function in the GenomicRanges R package (http://bioconductor.org/
packages/release/bioc/html/GenomicRanges.html) and the KnownGene data set from the University
of California, Santa Cruiz) (UCSC) (http://genome.ucsc.edu).
2.4. Estimation of DNA Methylation Age
DNAm age (also referred to as epigenetic age) was calculated from the neuronal samples profiled
with the Illumina Infinium 450 K platform as described in [43]. Briefly, the epigenetic clock is defined
as a multivariate linear model for predicting age based on the DNAm levels of 353 CpGs. These CpGs
and their weights (coefficient values) were chosen using several independent data sets by regressing
chronological age on CpGs. Predicted age, referred to as DNAm age, correlates with chronological
age in sorted cell types (CD4+ T cells, monocytes, B cells, glial cells, neurons), tissues, and organs,
including: whole blood, brain, breast, kidney, liver, lung, and saliva [43]. In our study, the epigenetic
clock method was implemented using publicly available R software scripts and in a web-based
calculator. The measure of epigenetic age acceleration was defined as a raw residual resulting from
regressing DNAm age on chronological age. By definition, epigenetic age acceleration does not correlat
with chronological age (r = 0).
2.5. Gene Ontology Functional Annotation Analysis
Gene ontology (GO) analysis was performed with the online software tool WebGestalt (www.
webgestalt.org, [79]). Enriched GO terms with adjusted p-values < 0.01 (Benjamini-Hochberg multiple
test adjustment) were considered statistically significant. In addition, we applied the cutoff of
N ≥ 10 genes for the minimal number of genes associated with a specific GO term. For the GO
analysis, we included the genes which had both hyperDMSs and hypoDMSs into both hyperDM gene
(G) and hypoDMG lists.
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2.6. Gene Expression Comparison between Glu- and GABA Neurons in the Human PFC
We employed our recently developed FANS-based protocol [69] to isolate two types of neuronal
nuclei: (1) the MGE-derived GABA neurons, and (2) glutamatergic neurons with a small (~10%)
admixture of non-MGE derived GABA neurons (denoted “Glu neurons”). PFC tissue samples from
3 control subjects were used for the experiments. After nuclear isolation, we employed an optimized
version of our RNA isolation protocol (see [69]). Specifically, 40,000 nuclei were sorted directly into
150 uL of Extraction Buffer from the PicoPure RNA isolation kit (ThermoFisher Scientific, Waltham,
MA USA). RNA isolation was then performed according to the kit protocol, with the inclusion of the
on-column DNAse treatment step, and the RNA was eluted in 15 uL Elution Buffer. RNA-seq libraries
were then prepared from 10 ng RNA using the SMARTer Stranded Pico RNA-seq library preparation
kit (Clontech, Mountain View, CA, USA), and sequenced on a HiSeq 2500 Illumina sequencer (Illumina,
San Diego, CA, USA) using paired-end 50 bp protocol. FASTQ files were trimmed to remove low quality
reads and adapters (using Scythe and Sickle software packages (https://github.com/vsbuffalo/scythe,
https://github.com/najoshi/sickle)), further trimmed by 3 bp from the 5′ end of read 1 as suggested
in the library kit protocol, and then mapped to human hg19 genome with STAR software [80]. EdgeR R
package [81] was used to perform differential expression (DE) analysis between GABA and Glu
neurons, with DE criteria of FDR < 0.01, abs(FoldChange) > 2, and a cutoff of 0.1 counts per million
(CPM). Supplementary Materials Table S2 presents the resulting lists of the DE genes.
3. Results
3.1. mOFC Neurons of Heroin Users Show Younger Epigenetic Age Than Neurons of Non-Addicted Individuals
It has been suggested that epigenetic age acceleration (that measures deviations between DNAm
age and chronological age) captures aspects of the biological age of the brain tissue [43]. We estimated
the epigenetic age (also known as DNAm age) of each neuronal mOFC sample by averaging the DNAm
levels of 353 CpGs profiled with the Illumina Infinium 450 K assay. As expected, neuronal DNAm
age was highly correlated with chronological age of subjects at the time of death across all samples
(correlation r = 0.85, p = 1.2 × 10−25; Figure 1a). We defined a measure of epigenetic age acceleration
as residual resulting from regressing DNAm age on chronological age. Thus, a positive value of age
acceleration indicates that the DNAm age of a sample is higher than expected based on chronological
age, whereas a negative value indicates that the DNAm age is younger than expected based on
chronological age. Whereas there were no differences in the neuronal age acceleration between the
control (N = 28) and suicide subjects (N = 22), the heroin subjects (N=37) showed a younger DNAm vs.
chronological age (p = 0.022; Figure 1b). A significantly younger neuronal epigenetic age in heroin
abusers was observed when we compared their age acceleration to that of all subjects who did not
abuse heroin (controls and suicides, N = 50; p = 0.0082; Figure 1c). The difference in age acceleration
was also observed when only young adults (subjects with chronological age <40) were considered
in the analysis (N = 32 and N = 36 for non-abusers and abusers, respectively; p = 0.0082; Figure 1d).
Because in our cohort the average age of heroin individuals is younger than control individuals, the
latter analysis provided additional validation of our findings using groups that were better balanced
by age.
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Figure 1. Neurons of heroin users show younger epigenetic age than neurons of non-addicted
individuals. (a) Correlation of neuronal DNAm age with chronological age of all subjects at time
of death. Red circles, heroin subjects; black circles, all other subjects; (b) Analysis of epigenetic age
acceleration in the neurons among heroin users, suicide subjects, and controls. The heroin subjects
have a younger DNAm vs. chronological age (p = 0.022); (c) Analysis of epigenetic age acceleration in
the neurons comparing heroin users and all subjects who did not abuse heroin. A significantly younger
neuronal DNAm age in heroin users was observed (p = 0.0082); (d) Same as in (c), but for subjects
with chronological age <40. The titles of the bar plots report the results of a non-parametric group
comparison test (Kruskal Wallis test).
3.2. Differential DNA Methylation Analysis
We compared samples from heroin users, suicide completers and control individuals to identify
differences in DNAm, adjusting for age, sex and tissue pH as covariates. After correcting for multiple
comparisons, we did not identify any differentially methylated (DM) CpGs sites between control and
suicide specimens using FDR < 0.1, whereas there were 3 sites that were DM between heroin users and
controls. We then used a more liberal threshold of significance (nominal p-value < 0.001). This resulted
in 454 DM sites (DMSs) between suicide and control subjects (DMsui sites) and 1311 sites that were
DM between heroin users and controls (DMher sites) (Supplementary Materials Table S3), and we used
these DM sites to focus on gene-set-level analyses. Among the DMher sites, there were 12 DMSs that
belonged to the CpH sequence context; these were excluded from the subsequent analysis, retaining
1298 DMher CpG sites. The absolute differences in average DNAm levels (beta values) were generally
small. Nevertheless, the majority of DMSs (1247 out of 1298 for DMher, and 431 out of 454 for DMsui
sites) showed beta value differences >1%, and the smallest beta value difference among the remaining
DMSs was 0.62%. Because of the relatively small number of DMSs with low (<1%) differences, we
retained all DMSs for the subsequent analyses. The DMher and DMsui sites represented largely
non-overlapping populations, with only 29 CpG probes showing significant DNAm changes in both
heroin users and suicide subjects compared with controls (Supplementary Materials Table S4).
In our cohort, the average age of heroin individuals was younger than control individuals.
In addition to including age as a covariate in our initial analysis, we also performed a secondary
analysis in order to better account for the role of age on our results. Specifically, we left out N = 10
oldest control individuals to balance the groups by age, analyzing N = 18 controls and N = 37 heroin
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individuals. In this new cohort there were no significant difference in age between the heroin and
control subjects (p = 0.09). We detected no noticeable effect of age on the regression estimates for the
heroin vs. control comparison (Supplementary Materials Figure S2), suggesting that we had properly
adjusted for age effects in the initial differential methylation analysis.
The information about the years of heroin use was available only for a subset of heroin subjects.
In order to test if the duration of heroin abuse influenced the differential methylation detected in our
study, we left out the heroin individuals (N = 14) which did not have the years-of-use information, and
using this filtered cohort, compared the results of the differential methylation analyses employing two
different linear models: (1) heroin/non-heroin status, and the covariates from the initial analysis, and
(2) Log10 (Years of Heroin Use + 1) and the covariates from the initial analysis. We found no significant
differences between the results from these two models (Supplementary Materials Figure S3).
We then defined differentially methylated genes (DMGs) based on the position of the DMSs (see
Materials and Methods). There were a total of 1159 unique DMGs associated with DMher sites (DMher
genes) and 407 genes associated with DMsui sites (DM genes) (Supplementary Materials Table S5);
87 genes were common for both DMher and DMsui gene lists. Among the DMher genes, 660 were
associated with at least one hyperDMS and 531 were associated with at least one hypoDMS, with
32 DMher genes associated with both a hyper- and a hypoDMS. There were 243 hyperDMsui genes
and 170 hypoDMsui genes, with 6 DMsui genes overlapping between these two lists (Supplementary
Materials Table S5). The DMGs that were present in both the hyperDMG and hypoDMG lists were
excluded from the analysis for neuron subtype specificity (see below).
3.3. Enrichment of Differentially Methylated Sites in Genomic Features and Regulatory Elements
We first asked if heroin- or suicide-associated hyper- or hypoDMSs were enriched (or depleted)
within genic features (i.e., promoters, exons, introns, entire gene bodies, intergenic regions), putative
regulatory elements (i.e., predicted enhancers) or CpG island-related features (i.e., CpG islands, shores,
or regions outside of islands and shores). We also tested if such enrichments could be specific to the
direction of the DNAm changes (hyper- vs. hypoDM).
We detected clear differences in the patterns of enrichment or depletion between hyper- and
hypoDMSs within many of the assessed features in the neurons from heroin users (Table 1, statistical
significance by Fisher’s exact test). In particular, within genic features, hyperDMher sites were strongly
enriched in exons and gene bodies, moderately enriched in introns, but significantly depleted from
promoters. In contrast, hypoDMher sites were enriched in promoters, but did not show significant
enrichment or depletion in other genic features.
Likewise, we detected differences between hyper- and hypoDMher sites in their pattern of
enrichment or depletion within putative transcriptional enhancers. The genomic coordinates of these
enhancers were based on the ChIP-seq peaks for the H3K27ac histone mark in the human PFC tissue
(data obtained from the NIH Roadmap Epigenomics Mapping Consortium, REMC [82]). We performed
this analysis separately for the H3K27ac peaks distal from transcription start site (TSS) (>1000 bp
distance), which are indicative of putative active enhancers, and for the TSS-proximal H3K27ac peaks,
which are indicative of active promoters. The hypoDMher sites were strongly enriched within distal
peaks (putative enhancers), whereas the hyperDMher sites showed neither enrichment nor depletion in
putative enhancers. In line with their enrichment in promoters, the hypoDMher sites were enriched in
proximal H3K27ac peaks, whereas the hyperDMher sites were strongly depleted from both promoters
and proximal H3K27ac peaks.
Both hyper- and hypoDMher sites were depleted from the genomic areas outside of CpG islands
or shores (the latter is defined as 2000 bp-width-areas at ≤2000 bp from the nearest CpG island).
In addition, hyperDMSs were slightly enriched in CpG islands, whereas hypoDMSs were enriched
within shores.
When the distribution of the suicide-associated DMSs within different genic features was analyzed,
only few significant results were detected. HyperDMsui sites were depleted within promoters as well
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as within proximal H3K27ac peaks, and were moderately enriched in exons, introns and gene bodies
(Table 1). No enrichment or depletion within any genic feature was found for hypoDMsui sites, which
might be explained by the relatively small number of DMs within this group.
Table 1. Enrichment or depletion of hyper- and hypomethylated sites (DMSs) within genomic features
and putative enhancers. Statistical significance was calculated by Fisher’s exact test. Promoters were
defined as regions within −1000 bp around the transcription start site. Significant (p-value < 0.01)
enrichments or depletions are shown in italic bold. Moderately significant (p-value < 0.05)
enrichments/depletions are shown in italic. H3K27ac ChIP-seq dataset was obtained from the Roadmap
Epigenomics Mapping Consortium database (REMC, http://www.roadmapepigenomics.org).
Genomic Features/
Putative Enhancers
Heroin DMSs Suicide DMSs
HyperDMSs HypoDMSs HyperDMSs HypoDMSs
Odds
Ratio p-Value
Odds
Ratio p-Value
Odds
Ratio p-Value
Odds
Ratio p-Value
Genic features
Exons 1.41 1.6× 10−4 0.85 0.19 1.36 0.045 0.85 0.54
Introns 1.21 0.013 0.97 0.75 1.31 0.030 1.15 0.38
Gene Body 1.26 0.0025 1.06 0.52 1.29 0.044 0.94 0.70
Intergenic 1.11 0.20 0.86 0.15 0.95 0.78 1.14 0.43
Promoters 0.47 4.8× 10−15 1.32 0.0034 0.53 6.1× 10−5 0.83 0.34
H3K27ac
ChIP-seq peaks
(human PFC)
Distal H3K27ac
peaks (enhancers) 1.18 0.07017 1.52 3.0× 10
−5 0.94 0.76 1.11 0.57
Proximal H3K27ac
peaks (promoters) 0.33 2.0× 10
−15 1.52 1.2× 10−4 0.67 0.048 0.60 0.052
CpG
island-related
features
CpG islands 1.18 0.03 1.02 0.85 0.91 0.52 0.86 0.42
Shores 1.16 0.075 1.22 0.044 0.86 0.42 0.85 0.29
Other regions 0.76 3.5× 10−4 0.85 0.06 1.22 0.12 1.19 0.26
3.4. Gene Ontology Analysis of Differentially Methylated Genes
To obtain insight into the possible biological implications of the detected DNAm changes in the
OFC of heroin users and suicide completers, we performed a functional annotation and enrichment
analysis of the DMGs using the online software tool WebGestalt (www.webgestalt.org [79]). This tool
integrates information from a number of public resources to assess the enrichment of gene sets in
various functional categories, and presents the results as a list as well as a tree-like diagram displaying
the hierarchical relationship of the enriched categories. We focused our analysis on the gene ontology
(GO) module of WebGestalt, which comprises 3 large subsets of GO terms: “Biological Process”,
“Molecular Function” and “Cellular Component”.
Notably, when hyperDMher genes (N = 660) and hypoDMher genes (N = 531) were analyzed, we
obtained essentially non-overlapping sets of enriched GO terms (Supplementary Materials Table S6 and
Figure S4A,B). Among the “Cellular_Component” GO subclass, the GO localization terms associated
with axons or synaptic compartments (“axon”, “synaptic membrane”) were enriched with the hyperDM
but not with the hypoDM gene set. In contrast, several GO categories associated with gene expression
regulation and transcription factor activity (“transcription factor binding”, “sequence-specific DNA
binding RNA polymerase II transcription factor activity” and others) were enriched in the hypoDM
but not in the hyperDM gene sets. In addition, “Biological_Process” GO terms “transmission of nerve
impulse”, “axonogenesis” and “cell–cell signaling” were specific to the hyperDM genes. On the other
hand, the hypoDM genes were enriched for the “regulation of neuron differentiation” GO term, which
included several transcription factors and growth factors (e.g., NGF).
When suicide-associated DMGs were analyzed, no significant enrichments were found for the
hypoDM gene set, which was only comprised of 170 genes. The hyperDMsui genes were enriched for
the “synaptic transmission” GO term, as well as for several other broad GO terms not directly related
to the nervous system function (Supplementary Materials Figure S4C).
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3.5. Neuronal Subtype-Specificity of Hyper- or Hypomethylated Genes
Our analysis of DM between heroin users or suicide subjects and controls was performed
in FANS-separated neuronal nuclei. This experimental design could not distinguish between
the contributions of specific neuronal subpopulations that exist in human PFC (e.g., excitatory
glutamatergic or inhibitory GABAergic neurons) to the observed differences in DNAm. To investigate
neuronal subtype-specificity of the hyper- and hypoDM genes, we compared the DMG sets with
genes that were differentially expressed (DE) between Glu projection neurons and MGE-derived
GABA interneurons in the PFC. MGE-derived GABA interneurons comprise ~60–70% of all cortical
GABA neurons, and express parvalbumin (PVALB) or somatostatin (SST) [83]. This population of
GABA neurons constitutes an essential component of inhibitory neuronal networks in the human and
mammalian cortex and has been implicated in many neurological and psychiatric diseases (including
schizophrenia, major depression, autism, and epilepsy) [84–87]. Therefore, it was important for the
interpretation of the results of our study to classify the DMGs as GABA- or Glu-specific. To this end,
we employed the FANS-based nuclei isolation protocol that was recently developed in our lab [69] and
that allowed us to separate and obtain neuronal nuclei from these neuronal populations. PFC tissues
obtained from 3 control subjects were analyzed.
The DE analysis identified a number of genes that were mostly expressed in Glu or GABA
neurons (Glu-specific and GABA-specific DE genes (DEGs), N = 1339 and 817 genes, respectively),
Next, we overlapped the DEG and DM gene sets and assessed the enrichment using the hypergeometric
distribution test. A significant difference in patterns of enrichment was observed between hyper-
and hypoDM genes (Table 2). For both DMher and DMsui genes, the hyperDMGs were strongly
enriched for Glu-specific DE genes, but not for GABA-specific genes (Table 2). In contrast, hypoDMher
and hypoDMsui genes showed no enrichment for Glu-specific DEGs. We, however, detected that
hypoDMsui genes were significantly enriched for GABA-specific DEGs (Table 2).
Table 2. Overlap between heroin or suicide DMGs and Glu- or GABA-specific DEGs. The overlaps
were calculated separately for hyper- and hypoDMGs. DMGs associated with both hyperDM- and
hypoDM sites were not included. Statistical significance was calculated with the hypergeometric test.
Significant overlaps (p-value < 0.01) are shown in bold. Only genes present in both the 450 K array
annotation and the DE analysis data set were included in the analysis (13,544 genes).
DM/DE Genes
Glu-DE Genes N = 1074 Genes GABA-DE Genes N = 701 Genes
Overlapping p-Value Overlapping p-Value
hyperDMGs N = 537 genes
heroin 70 2.2 × 10−5 27 0.59
hypoDMGs N = 405 genes
heroin 40 0.087 31 0.019
hyperDMGs N = 201 genes
suicide 34 1.9 × 10−5 11 0.47
hypoDMGs N = 133 genes
suicide 14 0.17 15 3.6 × 10−3
4. Discussion
In this study we employed the Illumina 450 K Infinium DNA methylation array to probe the
differences in DNAm in the OFC of heroin abusers who died of heroin overdose, suicide completers,
and control subjects who died of non-suicide causes. There was no evidence of any illicit drug use for
the latter two groups. We analyzed differential DNAm (1) between suicide completers and controls
and (2) between heroin users and controls. Applying a conservative nominal p-value (<0.001) we
detected 454 CpG sites that were DM between suicide and control subjects, and 1298 CpG DM sites
between heroin users and controls. We then assessed genomic features, neuron-subtype specificity as
well as functional categories and pathways that were associated with these DNAm differences.
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Whereas the number of DM sites and genes identified in the suicide vs. control comparison was
low and the results were difficult to interpret, we found noticeable differences for heroin-associated
DM sites and genes. In particular: (1) hyperDMher sites preferentially occurred in exons and more
generally in gene body regions. In contrast, no such enrichments were detected for hypoDMher
sites; (2) hypoDMher sites were significantly enriched in promoters and in the TSS-proximal
H3K27ac ChIP-seq peaks, whereas hyperDMher sites were dramatically depleted in these regions;
(3) hypoDMher sites were strongly enriched in TSS-distal H3K27ac ChIP-seq peaks (predicted
enhancers), whereas hyperDMher sites were not significantly overrepresented in these regulatory
regions; (4) at the gene level, hyperDMher genes were strongly enriched in Glu-specific, but not
in GABA-specific genes; (5) significant differences in gene ontology (GO) category enrichments
were found between hyper- and hypoDMher gene sets: hyperDMher genes were enriched in GO
categories for genes implicated in axonal and synaptic localization, as well as in synaptic transmission.
In contrast, hypoDMher genes were not enriched in these categories. Instead, hypoDMher sites were
overrepresented among genes with DNA binding and transcription factor activity. Thus, the hyper-
and hypomethylation in the specimens from heroin users are enriched in different neuronal subtypes
and different genomic contexts. These observations imply that different mechanisms of epigenetic
regulation might be recruited in different neuronal subtypes or specifically targeted to particular genic
features (promoters, exons, enhancers, etc.) in the context of opioid exposure. Collectively, these
findings suggest that the observed DNAm differences could represent functionally significant marks
of heroin-associated maladaptive plasticity in the OFC.
Notably, heroin-associated enrichment of the hyperDMGs in Glu-specific genes as well as in
synaptic and axonal genes is in agreement with the notion that drug-associated alterations in the
ventral PFC lead to reduced glutamatergic output from this region [30]. Our findings are also in
line with the recent study showing morphine-induced generation of silent (AMPA-receptor-deficient)
excitatory synapses in the rodent nucleus accumbens (NAc) [88]. These silent synapses were specifically
generated from the existing matured synapses in the NAc D2-type medium spiny neurons (MSNs),
and likely represented an intermediate step in the subsequent synaptic elimination, thus reducing the
excitatory drive to the D2-type MSNs in the NAc from other brain regions. It is, therefore, plausible that
our finding of increased DNAm at the genes involved in axonogenesis, axonal and synaptic function
in the OFC of heroin users may represent a presynaptic mechanism contributing to the weakening
and elimination of the excitatory synapses of the OFC projections to the NAc. It is important to note
that the mechanism of the silent synapse formation described above was specific to morphine but
was different in the case of cocaine treatment [88], and the cohort of the drug abusers employed in
our study consisted exclusively of heroin users, who did not abuse other illicit drugs (e.g., cocaine
or amphetamine).
Whereas our approach was mostly focused on the analysis of sets of DMSs or DMGs, inspecting
these data allowed us to identify a number of individual genes that could potentially have major
implications for heroin addiction or suicide. Among the heroin-associated DMGs are SLC17A7 (gene
coding for glutamate transporter; probe ID cg16890796), OPRL1 (that encodes an opioid receptor-like
protein, nociceptin receptor, which has been implicated in alcohol and other drug reward pathways [89];
cg24210478, cg23205874), as well as TET3 (cg11236515). The latter encodes one of the 3 Ten-Eleven
Translocation enzymes that oxidize methylcytosine to produce the hydromethylcytosine DNA mark,
and thus could alter the inhibitory character of DNAm and/or contribute to DNA demethylation.
Of note, TET1, another member of the TET family, has been recently implicated in the mechanism
of cocaine action in the NAc [22]. Another heroin use-associated DMG is ARC (cg08387463). ARC is
an immediate early gene (IEG), which can be upregulated in an activity-dependent manner [90].
It encodes Arc/Arg3.1 protein implicated in synaptic plasticity, and in particular, in the mechanisms
of morphine addiction in the NAc [91]. Here we detected significant hypermethylation of a CpG site
within the first exon of ARC, at ~1300 bp distance from the TSS. Increased DNAm of ARC (which
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contrasts with increased ARC expression in the NAc as found in other studies) might be a specific
signature of heroin addiction in the OFC.
Among the suicide-associated DNAm genes, of particular interest are PRRT1 and SORBS2.
For both of these genes, more than one hyperDMS was detected in suicide completers vs. controls,
(7 hyperDMSs for PRRT1 (cg18419271, cg02925367, cg27067781, cg21035875, cg14757228, cg17626960,
cg14531663)—the largest number of sites for any suicide-associated DMG in our study, and
3 hyperDMSs for SORBS2, cg09555153, cg04392082, cg22328746). PRRT1 encodes a little-studied
auxiliary subunit of the AMPA receptor, and was shown to colocalize with extrasynaptic GluA1 puncta
in primary neuronal cultures [92]. The SORBS2 gene encodes ArgBP2 protein and is alternatively
spliced in the brain to encode a neuron-specific nArgBP2 isoform. In mice, nArgBP2 is highly expressed
in many brain regions, including cortex, and localizes at dendritic spines. Knockout of Sorbs2 leads to
reduced dendritic complexity, as well as to a reduced acoustic startle response, and defective long-term
object recognition memory and contextual fear memory [93]. It was also shown that nArgBP2 serves
as a major regulator of dendritic spine morphology at excitatory synapses, potentially implicating this
protein as a “hub” molecule in various neuropsychiatric disorders, including bipolar disorder [94].
Another intriguing finding of our study is the discovery that the OFC neurons of heroin users
show a younger epigenetic age than the control subjects. This finding will require confirmation by other
studies and is not straightforward to interpret. However, significant cellular and molecular changes
were reported with repeated exposure to drugs of abuse, and the “neural rejuvenation” hypothesis
has been recently proposed to conceptualize some of these changes, with one of the main defining
features being the formation of immature, silent synapses [95]. Silent synapses can be generated de
novo, as in the case of cocaine action in the NAc, but can also arise from existing, mature synapses,
as was demonstrated in the case of morphine action (see above) [88,95]. It is plausible that the latter
may be relevant to the differences in the neuronal epigenetic age between heroin abusers and controls
uncovered in our study.
To the best of our knowledge, the present study constitutes the first genome-wide DNAm profiling
of human postmortem brain samples (specifically, neuronal nuclei from the OFC) of heroin abusers
vs. control subjects. It also contributes to a growing list of studies exploring DNAm in the suicide
brain [96–98]. In future studies, it would be of much interest to explore some of the findings of
the current work in independent (and larger) cohorts and using tissue specimens from different
brain regions relevant for drug addiction. Such studies should preferably involve both epigenetic
profiling and RNA-seq experiments, and, when possible, should be conducted using cell type- or
subtype-enriched preparations.
5. Conclusions
We investigated the genome-wide DNAme differences in the OFC of individuals who abused
heroin and died of heroin overdose and of individuals who did not use heroin and died by suicide vs.
control subjects who did not use illicit drugs and died of non-suicide causes. We identified numerous
CpG sites that were differentially methylated between heroin users and control individuals as well
as between suicide victims and controls. We found that the hyper- and hypomethylated CpG sites
and associated genes in the heroin users were enriched in different neuronal subtypes and different
genomic contexts. These observations suggest that different modes of epigenetic regulation might be
recruited in different neuronal subtypes or specifically targeted to particular genic features and/or
regulatory elements (e.g., promoters, gene bodies or enhancers) in the context of heroin exposure.
We also found that the DNAm-based “epigenetic age” of neurons from heroin users was younger than
that in controls. Suicide-related differences in DNAm were subtle and difficult to interpret. Collectively,
these findings implicate heroin-induced epigenetic remodeling in the previously reported functional
abnormalities of the ventral mPFC in heroin abusers.
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Table S1: Summary of demographics for the specimens used in the study, Table S2: Analysis of differential
gene expression (DE) between Glu- and GABA-neurons, Table S3: Differentially methylated sites (DMSs) detected
when comparing heroin users vs. control subjects, or suicide completers vs. control subjects, Table S4: Overlap
between heroin associated- and suicide-associated DM sites (hyper- or hypoDMSs), Table S5: Differentially
methylated genes (DMGs) between heroin users vs. control subjects, or between suicide completers vs. control
subjects, Table S6: Gene ontology functional annotation analysis of DMG sets using WebGestalt tool, Figure S1:
Estimated proportions of NeuN(+) and NeuN(−) nuclei in the FACS-separated neuronal nuclear preparations
from the current study, Figure S2: Comparison of DM values for N = 1298 heroin vs. control DM sites between
the initial analysis and the analysis which excluded 10 oldest control individuals, Figure S3: Assessment of
influence of the duration of heroin use on the DM values for N = 1298 heroin vs. control DMSs, Figure S4: Graphic
representation of the gene ontology annotation analysis of DMG sets using WebGestalt tool. (A): hyperDMheroin
gene set, (B): hypoDMheroin gene set, (C): hyperDMsuicide gene set. No enriched gene ontology terms were
found for hypoDMsuicide gene set. Data Availability: Data are available at GEO (GSE98203).
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